Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Promising results in metastatic bladder cancer using immunotherapy

ESMO 2016

Published: 10 Oct 2016

Views: 2155

Rating:

Save

Dr Matthew Galsky - Mount Sinai, New York, USA

Dr Galsky talks to ecancertv at ESMO 2016 about promising results for immunotherapy in first and second line treatment of metastatic bladder cancer in two phase II trials.

Read the news story or watch an interview with Dr Balar for more.

Related Videos

Isatuximab plus lenalidomide and dexamethasone with bortezomib as a new...

Prof Xavier Leleu - CHU de Poitiers, Poitiers, France

Isatuximab plus lenalidomide and dexamethasone with bortezomib as a new standard of care for NDMM TI non-frail patients ( Prof Xavier Leleu - CHU de Poitiers, Poitiers, France )

Made to measure: Choosing the optimal regimen in transplant-eligible NDMM

Dr Elias Mai - Heidelberg University, Heidelberg, Germany

Made to measure: Choosing the optimal regimen in transplant-eligible NDMM ( Dr Elias Mai - Heidelberg University, Heidelberg, Germany )

ESMO 2024: Latest updates in mRCC

Dr Javier Puente, Dr Guillermo De Velasco, Dr Cristina Suárez and Prof Stéphane...

ESMO 2024: Latest updates in mRCC ( Dr Javier Puente, Dr Guillermo De Velasco, Dr Cristina Suárez and Prof Stéphane Oudard )

ESMO 2024: Optimising the personalisation of prostate cancer treatment

Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof...

ESMO 2024: Optimising the personalisation of prostate cancer treatment ( Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof Gunhild von Amsberg )

EAU 2024: Bladder cancer latest

Dr Bernadett Szabados, Dr Félix Guerrero-Ramos, Dr Yohann Loriot, Prof Andrea...

EAU 2024: Bladder cancer latest ( Dr Bernadett Szabados, Dr Félix Guerrero-Ramos, Dr Yohann Loriot, Prof Andrea Necchi and Dr Cosimo De Nunzio )

OncoAlert round up July 28th to August 3rd, 2023

Dr Gil Morgan - Executive Director, OncoAlert

OncoAlert round up July 28th to August 3rd, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )

mRCC: Atezolizumab after progression with prior ICI treatment shows no benefit...

Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA

mRCC: Atezolizumab after progression with prior ICI treatment shows no benefit and increases toxicity ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )

CG0070 plus pembro shows promising efficacy in NMIBC unresponsive to BCG

Dr Roger Li - Moffitt Cancer Center, Tampa, USA

CG0070 plus pembro shows promising efficacy in NMIBC unresponsive to BCG ( Dr Roger Li - Moffitt Cancer Center, Tampa, USA )

Pembro monotherapy for participants with BCG–unresponsive HR NMIBC shows anti...

Prof Andrea Necchi - The Vita-Salute San Raffaele University, Milan, Italy

Pembro monotherapy for participants with BCG–unresponsive HR NMIBC shows anti-tumour activity ( Prof Andrea Necchi - The Vita-Salute San Raffaele University, Milan, Italy )

More from ecancer